Gilad Glick is currently Vice President, Venture Investments for Johnson & Johnson Innovation Fund heading the activity in Israel for both (Bio)Pharma and MedTech and Europe for MedTech. Prior to that he led Itamar Medical as CEO, a sleep apnea diagnostic and digital care pathway publicly traded company (TASE, NASDAQ) for over 8 years before it was sold to ZOLL Medical , a world leader in the cardiac defibrillation market in late 2021. Prior to joining Itamar Medical in 2013, Gilad had an 17-year career in medical devices spanning a number of countries in Europe and the US and in a variety of functional areas including sales, marketing, service and research and development all with Johnson & Johnson . In his last role Gilad served as Vice President Global Sales and Marketing for Biosense Webster, a Johnson & Johnson company, at the time a $1.5B revenue operating company which oversees all strategic and commercial activities.

Gilad is a 8400 Heath Network member graduating cohort 4 , a founder of the MedTech Commercialization Institute and a Board of Directors member at Beta Bionics (Private).